Figure 5
The effect of apremilast on the expression of CD3- and F4/80-positive cells in bleomycin-induced dermal fibrosis in mice. Mice (each group, n = 4) were injected with either PBS or bleomycin subcutaneously on the back five times a week for four weeks. In the apremilast treatment group, 5 mg/kg/day apremilast was administered intraperitoneally concomitant with bleomycin. (a) Representative images of immunohistochemical analysis with CD3 and F4/80 staining the skin in mice treated with subcutaneous PBS, bleomycin, and bleomycin plus 5 mg/kg/day apremilast. (b) The number of CD3 and F4/80 positive cells in the lesional skin at 100 × magnification. Scale bar 100 μm. *p < 0.05. n.s. not significant, Apre apremilast, Bleo bleomycin. See Fig. 1 for other abbreviations.
